Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study
{{output}}
Background/aims: The GRAVITI (NCT05197049) study demonstrated efficacy and safety of guselkumab, a dual-acting interleukin- 23p19 subunit inhibitor, as subcutaneous (SC) induction and maintenance therapy in participants with mode... ...
